Rare combination of ANCA-associated glomerulonephritis with systemic lupus erythematosus
- Autores: Voloshinova E.V.1, Grigoryeva E.V.1, Nikitina N.M.1
-
Afiliações:
- V.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of Russia
- Edição: Volume 9, Nº 3 (2023)
- Páginas: 78-82
- Seção: CLINICAL CASE
- URL: https://journals.eco-vector.com/2412-4036/article/view/510122
- DOI: https://doi.org/10.18565/therapy.2023.3.78–82
- ID: 510122
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Lupus nephritis is a classic immunocomplex glomerulonephritis. Kidney damage associated with antineutrophil cytoplasmic antibodies is a low-immune focal and segmental necrotizing/lunate glomerulonephritis that could be developed both separately and as part of systemic vasculitis. The aim of the research is to present and analyze an extremely rare clinical observation of female patient with systemic lupus erythematosus, identified antibodies to the cytoplasm of neutrophils and morphologically verified low-immune glomerulonephritis. The choice of treatment tactics in current clinical situation is substantiated.
Texto integral
Sobre autores
Elena Voloshinova
V.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of Russia
Autor responsável pela correspondência
Email: voloshinovaelena@mail.ru
ORCID ID: 0000-0002-6883-0567
PhD in Medical Sciences, Associate Professor of the Department of Hospital Therapy
Rússia, SaratovElena Grigoryeva
V.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of Russia
Email: lek133@yandex.ru
ORCID ID: 0000-0001-6064-560X
PhD in Medical Sciences, Associate Professor of the Department of Hospital Therapy
Rússia, SaratovNatalia Nikitina
V.I. Razumovsky Saratov State Medical University of the Ministry of Healthcare of Russia
Email: nikina02@yandex.ru
ORCID ID: 0000-0002-0313-1191
MD, Professor of the Department of Hospital Therapy
Rússia, SaratovBibliografia
- Kamen D.L. Environmental influences on systemic lupus erythematosus expression, rheumatic disease clinics of North America. 2014; 40(3): 401–11. https://dx.doi.org/10.1016/j.rdc.2014.05.003.
- Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012; 11(8): 593–95. https://dx.doi.org/10.1016/J.AUTREV.2011.10.020.
- Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1): 1–11. https://dx.doi.org/10.1002/art.37715.
- Shimizu T., Morita T., Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (Oxford). 2020; 59(5): 959–67. https://dx.doi.org/10.1093/rheumatology/kez311.
- Choi M.Y., Fritzler M.J. Autoantibodies in SLE: Prediction and the p value matrix. Lupus. 2019; 28(11): 1285–93. https://dx.doi.org/10.1177/0961203319868531.
- Leuchten N., Hoyer A., Brinks R. et al. Performance of antinuclear antibodies for classifying systemic lupus erythematosus: A systematic literature review and meta-regression of diagnostic data. Arthritis Care Res (Hoboken). 2018; 70(3): 428–38. https://dx.doi.org/10.1002/ACR.23292.
- Hellmich B., Flossman O., Gross W.L. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007; 66(5): 605–17. https://dx.doi.org/10.1136/ard.2006.062711.
- Miloslavsky E.M., Specks U., Merkel P.A. et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013; 65(9): 2441–49. https://dx.doi.org/10.1002/art.38044.
- Fauzi A.R., Kong N.C., Chua M.K. et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus: Prevalence, disease activity correlations and organ system associations. Med J Malaysia. 2004; 59(3): 372–77.
- Старовойтова М. Н., Десинова О. В., Гусева Н. Г. Перекрестные формы системной склеродермии. Научно-практическая ревматология. 2007; 45(1): 52–57. [Starovoitova M.N., Desinova O.V., Guseva N.G. Cross forms of systemic scleroderma. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology. 2007; 45(1): 52–57 (In Russ.)]. EDN: HZSMZR.
- Jarrot P.-A., Chiche L., Hervier B. et al. Systemic lupus erythematosus and antineutrophil cytoplasmic antibodyassociated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis». Medicine. 2016; 95(22): e3748. https://dx.doi.org/10.1097/MD.0000000000003748.
- Itikyala S., Pattanaik D., Raza S. Systemic lupus erythematosus (SLE) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Overlap syndrome: Case report and review of the literature. Case Rep Rheumatol. 2019; 2019: 5013904. https://dx.doi.org/10.1155/2019/5013904.
- Makiishi T., Shirase T., Yamamoto S., Maeda S. AP-VAS 2012 case report: A case of lupus nephritis with predominant synchronous cellular crescent formation and myeloperoxidase-antineutrophil cytoplasmic antibody seropositivity. CEN Case Rep. 2013; 2(2): 134–38. https://dx.doi.org/10.1007/s13730-012-0046-x.
- Moiseev S., Cohen Tervaert J.W., Arimura Y. et al. 2020 International consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020; 19(9): 102618. https://dx.doi.org/10.1016/j.autrev.2020.102618.
- Бекетова Т.В. Международные рекомендации по лечению АНЦА-ассоциированных системных васкулитов. Современная ревматология. 2019; 13(1): 19–25. [Beketova T.V. International guidelines for the treatment of ANCA-associated systemic vasculitis. Sovremennaya revmatologiya = Modern Rheumatology. 2019; 13(1): 19–25 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-1-19-25. EDN: XEWKJG.
- Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа. 2020; с. 131. [Russian clinical guidelines. Rheumatology. Ed. by Nasonov E.L. Moscow: GEOTAR-Media. 2020; p. 131 (In Russ.)]. ISBN: 978-5-9704-5398-8.